Immunomodulatory Activity and Effectiveness of Macrolides in Chronic Airway Disease

Chest

Volumn 125, Issue 2 SUPPL., 2004, Pages 70S-78S

  Rubin, Bruce K ^a   Henke, Markus O ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Azithromycin; Clarithromycin; Cystic fibrosis; Cytokines; Diffuse panbronchiolitis; Erythromycin; Macrolide antibiotics; Neutrophil; Troleandomycin

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; CLARITHROMYCIN; CORTICOSTEROID; ERYTHROMYCIN; IMMUNOMODULATING AGENT; MACROLIDE; PHOSPHOLIPID; ROXITHROMYCIN; TROLEANDOMYCIN;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; ASIAN; BRONCHIOLITIS; CHRONIC INFLAMMATION; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; CYTOKINE RELEASE; DIFFUSE PANBRONCHIOLITIS; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; JAPAN; LOW DRUG DOSE; LUNG FUNCTION; MUCUS SECRETION; PRIORITY JOURNAL;

EID: 1042288092     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.2_suppl.70S     Document Type: Article

References (47)

1. Itkin IH, Menzel ML. The use of macrolide antibiotic substances in the treatment of asthma. J Allergy 1970; 45:146-162
2. Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 1998; 157:1829-1832
3. Kadota J, Mukae H, Ishii H, et al. Long-term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003; 97:844-850
4. Ichikawa Y, Hotta M, Sumita S, et al. Reversible airway lesions in diffuse panbronchiolitis: detection by high-resolution computed tomography. Chest 1995; 107:120-125
5. Takeda H, Miura H, Kawahira M, et al. Long-term administration study on TE-031 (A-56268) in the treatment of diffuse panbronchiolitis. Kansenshogaku Zasshi 1989; 63:71-78
6. Rubin BK, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs 2000; 1:169-172
7. Culic O, Erakovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429:209-229
8. Jaffe A, Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001; 31:464-473
9. Spector S, Katz F, Farr R. Troleandomycin: effectiveness in steroid-dependent asthma and bronchitis. J Allergy Clin Immunol 1974; 54:367-379
10. Wald JA, Friedman BF, Farr RS. An improved protocol for the use of troleandomycin (TAO) in the treatment of steroid-requiring asthma. J Allergy Clin Immunol 1986; 78:36-43
11. Siracusa A, Brugnami G, Fiordi T, et al. Troleandomycin in the treatment of difficult asthma. J Allergy Clin Immunol 1993; 92:677-682
12. Zeiger RS, Schatz M, Sperling W, et al. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma. J Allergy Clin Immunol 1980; 66:438-446
13. Flotte TR, Loughlin GM. Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma. Pediatr Pulmonol 1991; 10:178-182
14. Kamada AK, Hill MR, Ikle DN, et al. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma. J Allergy Clin Immunol 1993; 91:873-882
15. Szefler SJ, Rose JQ, Ellis EF, et al. The effect of troleandomycin on methylprednisolone elimination. J Allergy Clin Immunol 1980; 66:447-451
16. Szefler SJ, Brenner M, Jusko WJ, et al. Dose- and time-related effect of troleandomycin on methylprednisolone elimination. Clin Pharmacol Ther 1982; 32:166-171
17. Ball BD, Hill MR, Brenner M, et al. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children. Ann Allergy 1990; 65:37-45
18. Alvarez J, Surs W, Leung DY, et al. Steroid-resistant asthma: immunologic and pharmacologic features. J Allergy Clin Immunol 1992; 89:714-721
19. Tamaoki J, Takeyama K, Tagaya E, et al. Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections. Antimicrob Agents Chemother 1995; 39:1688-1690
20. Rubin BK, Druce H, Ramirez OE, et al. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155:2018-2023
21. Koh YY, Lee MH, Sun YH, et al. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: a double-blind, placebo-controlled study. Eur Respir J 1997; 10:994-999
22. Shimizu T, Shimizu S, Hattori R, et al. In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. Am J Respir Crit Care Med 2003; 168:581-587
23. Tamaoki J, Takeyama K, Yamawaki I, et al. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition by macrolides. Am J Physiol 1997; 272:L15-L19
24. Brugiere O, Milleron B, Antoine M, et al. Diffuse panbronchiolitis in an Asian immigrant. Thorax 1996; 51:1065-1067
25. Fitzgerald JE, King TE Jr, Lynch DA, et al. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med 1996; 154:497-503
26. Krishnan P, Thachil R, Gillego V. Diffuse panbronchiolitis: a treatable sinobronchial disease in need of recognition in the United States. Chest 2002; 121:659-661
27. Kudoh S, Uetake T, Hagiwara K, et al. Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 1987; 25:632-642
28. Nagai H, Shishido H, Yoneda R, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58:145-149
29. Fujii T, Kadota J, Kawakami K, et al. Long term effect of erythromycin therapy in patients with chronic Pseudomonas aeruginosa infection. Thorax 1995; 50:1246-1252
30. Kadota J, Sakito O, Kohno S, et al. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis 1993; 147:153-159
31. Sakito O, Kadota J, Kohno S, et al. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63:42-48
32. Desaki M, Takizawa H, Ohtoshi T, et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000; 267:124-128
33. Zhao DM, Xue HH, Chida K, et al. Effect of erythromycin on ATP-induced intracellular calcium response in A549 cells. Am J Physiol Lung Cell Mol Physiol 2000; 278:L726-L736
34. Feldman C, Anderson R, Theron AJ, et al. Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro. Inflammation 1997; 21:655-665
35. Ichikawa Y, Ninomiya H, Koga H, et al. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis 1992; 146:196-203
36. Kadota J, Mukae H, Tomono K, et al. High concentrations of beta-chemokines in BAL fluid of patients with diffuse panbronchiolitis. Chest 2001; 120:602-607
37. Mukae H, Kadota J, Ashitani J, et al. Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis. Chest 1997; 112:1615-1621
38. Ashitani J, Mukae H, Nakazato M, et al. Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis. Eur Respir J 1998; 11:104-111
39. Hiratsuka T, Mukae H, Iiboshi H, et al. Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 2003; 58:425-430
40. Mukae H, Kadota J, Kohno S, et al. Increase in activated CD8+ cells in bronchoalveolar lavage fluid in patients with diffuse panbronchiolitis. Am J Respir Crit Care Med 1995; 152:613-618
41. Schoni M. Macrolide antibiotic therapy in patients with cystic fibrosis. Swiss Med Wkly 2003; 133:297-301
42. Peckham DG. Macrolide antibiotics and cystic fibrosis. Thorax 2002; 57:189-190
43. Jaffe A, Francis J, Rosenthal M, et al. Long-term azithromycin may improve lung function in children with cystic fibrosis [letter]. Lancet 1998; 351:420
44. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360:978-984
45. Ripoll L, Reinert P, Pepin LF, et al. Interaction of macrolides with alpha dornase during DNA hydrolysis. J Antimicrob Chemother 1996; 37:987-991
46. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212-216
47. Ordonez CL, Stulbarg M, Grundland H, et al. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001; 32:29-37